Apocynin
产品说明书
 |
同义名 : | 4'-羟基-3'-甲氧基苯乙酮 ;Acetovanillone; Acetoguaiacone; NSC 209524; NSC 2146 |
| CAS号 : | 498-02-2 | |
| 货号 : | A113062 | |
| 分子式 : | C9H10O3 | |
| 纯度 : | 98% | |
| 分子量 : | 166.17 | |
| MDL号 : | MFCD00008747 | |
| 存储条件： |
Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(631.87 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 3 mg/mL(18.05 mM)，配合低频超声，并水浴加热至45℃助溶 |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Apocynin is a most widely studied pan-NADPH-oxidase inhibitor and a scavenger of hydrogen peroxide, as well as inhibits rho kinases. Apocynin could eliminate hydrogen peroxid in a dose-dependent manner at concentration ranging in 3-100μM. Intraperitoneal injection with Apocynin at dose of 5mg/kg reduced lung injury and blocked NADPH oxidase activation in lung tissues by carrageenan in mice. The administration of Apocynin significantly reduced ICAM-1, P-selectin induced by carrageenan and attenuated neutrophil infiltration into the lung tissue. Also Apocynin attenuated carrageenan-induced TNF-α and IL-1β, iNOS expression, Fas ligand, apoptosis and Bax expression, as well as prevented carrageenan-induced inhibition of Bcl-2 expression and activation of NF-κB pathway and MAPK pathway at 4h post carrageenan injection. Some study showed that Apocynin may work as an antioxidant more than a NADPH oxidase inhibitor for apocynin failed to inhibit superoxide anion generation in HEK293 cells overexpressing NADPH oxidase isoforms (Nox1, Nox2, or Nox4). | ||
| 作用机制 | Apocynin is an oxidase assembly inhibitor which can inhibit association of p47phox with membrane-bound heterodimer.[5] | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03376555 | Microvascular Dysfunction | Phase 1 Phase 2 | Recruiting | June 30, 2019 | United States, Pennsylvania ... 展开 >> Pennsylvania State University Recruiting University Park, Pennsylvania, United States, 16802 收起 << |
| NCT03680573 | Cardiovascular Diseases ... 展开 >> Cardiovascular Risk Factor Vasoconstriction 收起 << | Phase 1 | Completed | - | United States, Texas ... 展开 >> Engineering Research Building Arlington, Texas, United States, 76019 收起 << |
| NCT03680638 | Cardiovascular Diseases ... 展开 >> Cardiovascular Risk Factor Vasodilation 收起 << | Phase 1 | Completed | - | United States, Texas ... 展开 >> Engineering Research Building Arlington, Texas, United States, 76019 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
6.02mL 1.20mL 0.60mL |
30.09mL 6.02mL 3.01mL |
60.18mL 12.04mL 6.02mL |
| 参考文献 |
|---|